We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

New Drug Delivery System Targets Diseases at a Genetic Level

News   Dec 06, 2017 | Original story from University of Connecticut

 
New Drug Delivery System Targets Diseases at a Genetic Level

Enzyme-triggered degradation of a drug loaded peptide-crosslinked nucleic acid nanocapsule. First a peptide is crosslinked at the nanoparticle surface (1), then an enzyme recognizes the peptide crosslinker (2), and finally the enzyme cleavage leads to the release of the drug and any intact DNA (3). Credit: (Artwork by Joseph Luciani/UConn)

 
 
 

RELATED ARTICLES

Therapy Combo Promising in Small Cell Lung Cancer Model

News

A combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair achieved significant tumor regression in mouse models of small cell lung cancer, suggesting a promising new approach for treating patients with this aggressive cancer.

READ MORE

Open Science Drug Discovery Approach Targets Neurodegenerative Disease

News

Parkinson’s disease and Amyotrophic Lateral Sclerosis, or ALS, are the newest frontiers for open science drug discovery, a global movement led by University of Toronto researchers that puts knowledge sharing and medication affordability ahead of patents and profits.

READ MORE

100,000-person Study Investigates Association Between Antiepileptic Drugs and Dementia

News

A study has investigated the hypothetical association between antiepilipetic drug use and dementia risk in 101,150 individuals receiving treatment from more than 1,400 physicians in Germany.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Analysis & Separations Cell Science Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE